Incyte company profile
Company profile
Incyte has 2,844 employees and is headquartered in Wilmington, United States.
JAKAFI, ICLUSIG, MONJUVI, NIKTIMVO, PEMAZYRE and ZYNYZ are the Incyte Corporation medicines most widely known, and the company discovers, develops and commercializes therapeutics. Its marketed products treat myelofibrosis, polycythemia vera, chronic myeloid leukemia, diffuse large B-cell lymphoma and Merkel cell carcinoma, while clinical-stage candidates target ovarian cancer, atopic dermatitis, hidradenitis suppurativa and vitiligo. Products are sold to specialty and retail pharmacies, hospital pharmacies and distributors in the United States, Europe, Canada and Japan.
In the fiscal year ended December 2025, Incyte reported revenue of $5.1 billion, up 21.2% from the previous year, and net income of $1.3 billion. The United States accounted for 93.4% of revenue and Europe for 6.3%. The company had 2,844 employees and is headquartered in Wilmington, Delaware, where it was incorporated in 1991. It was formerly known as Incyte Genomics Inc and took its current name in March 2003.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 1801 Augustine Cut-Off, 19803, Wilmington
- Employees
- 2,844
- Chief executive
- William Meury
- Founded
- 1991
- Fiscal year
- January - December
- Listing
- INCY · NASDAQ
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US45337C1027
- Website
- incyte.com
Incyte and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| IncyteINCY | United States | $24.36B | 2,844 | 32.2% | 61.0 |
| Alnylam PharmaceuticalsALNY | United States | $22.11B | 2,500 | 19.5% | 8.34 |
| InsmedINSM | United States | $26.96B | 1,664 | -41.7% | — |
| BioNTechBNTX | United States | $21.22B | 7,807 | -55.4% | — |
| Roivant SciencesROIV | United States | $28.64B | 721 | -3,226.3% | — |
| Ascendis PharmaASND | United States | $18.06B | 1,189 | 30.9% | 18.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
